These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 35100006)

  • 1. Budget impact analysis of trilaciclib for decreasing the incidence of chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer in the United States.
    Abraham I; Goyal A; Deniz B; Moran D; Chioda M; MacDonald KM; Huang H
    J Manag Care Spec Pharm; 2022 Apr; 28(4):435-448. PubMed ID: 35100006
    [No Abstract]   [Full Text] [Related]  

  • 2. Trilaciclib and the economic value of multilineage myeloprotection from chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer treated with first-line chemotherapy.
    Abraham I; Onyekwere U; Deniz B; Moran D; Chioda M; MacDonald K; Huang H
    J Med Econ; 2021 Nov; 24(sup1):71-83. PubMed ID: 34873975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The budget impact of adding pralsetinib to a US health plan formulary for treatment of non-small cell lung cancer and thyroid cancer with
    Duff S; Bargiacchi F; Norregaard C; Brener M; Sullivan E
    J Manag Care Spec Pharm; 2022 Feb; 28(2):218-231. PubMed ID: 34726500
    [No Abstract]   [Full Text] [Related]  

  • 4. Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy-induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials.
    Ferrarotto R; Anderson I; Medgyasszay B; García-Campelo MR; Edenfield W; Feinstein TM; Johnson JM; Kalmadi S; Lammers PE; Sanchez-Hernandez A; Pritchett Y; Morris SR; Malik RK; Csőszi T
    Cancer Med; 2021 Sep; 10(17):5748-5756. PubMed ID: 34405547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploratory composite endpoint demonstrates benefit of trilaciclib across multiple clinically meaningful components of myeloprotection in patients with small cell lung cancer.
    Dómine Gómez M; Csőszi T; Jaal J; Kudaba I; Nikolov K; Radosavljevic D; Xiao J; Horton JK; Malik RK; Subramanian J
    Int J Cancer; 2021 Oct; 149(7):1463-1472. PubMed ID: 34109630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Budget impact analysis of darolutamide for treatment of nonmetastatic castration-resistant prostate cancer.
    Appukkuttan S; Farej R; Miles L; Purser M; Wen L
    J Manag Care Spec Pharm; 2021 Feb; 27(2):166-174. PubMed ID: 33141615
    [No Abstract]   [Full Text] [Related]  

  • 7. The Budget Impact of Including Necitumumab on the Formulary for First-Line Treatment of Metastatic Squamous Non-Small Cell Lung Cancer: U.S. Commercial Payer and Medicare Perspectives.
    Bly CA; Molife C; Brown J; Tawney MK; Carter GC; Cinfio FN; Klein RW
    J Manag Care Spec Pharm; 2018 Jun; 24(6):534-543. PubMed ID: 29799326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results from Three Phase II Randomized, Double-Blind, Placebo-Controlled Studies.
    Weiss J; Goldschmidt J; Andric Z; Dragnev KH; Gwaltney C; Skaltsa K; Pritchett Y; Antal JM; Morris SR; Daniel D
    Clin Lung Cancer; 2021 Sep; 22(5):449-460. PubMed ID: 33895103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient-Administered Biologic and Biosimilar Filgrastim May Offer More Affordable Options for Patients with Nonmyeloid Malignancies Receiving Chemotherapy in the United States: A Budget Impact Analysis from the Payer Perspective.
    Trautman H; Szabo E; James E; Tang B
    J Manag Care Spec Pharm; 2019 Jan; 25(1):94-101. PubMed ID: 30084301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Budgetary Impact of Cabazitaxel Use After Docetaxel Treatment for Metastatic Castration-Resistant Prostate Cancer.
    Flannery K; Drea E; Hudspeth L; Corman S; Gao X; Xue M; Miao R
    J Manag Care Spec Pharm; 2017 Apr; 23(4):416-426. PubMed ID: 28345444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study.
    Hart LL; Ferrarotto R; Andric ZG; Beck JT; Subramanian J; Radosavljevic DZ; Zaric B; Hanna WT; Aljumaily R; Owonikoko TK; Verhoeven D; Xiao J; Morris SR; Antal JM; Hussein MA
    Adv Ther; 2021 Jan; 38(1):350-365. PubMed ID: 33123968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myeloprotection with trilaciclib in Chinese patients with extensive-stage small cell lung cancer receiving chemotherapy: Results from a randomized, double-blind, placebo-controlled phase III study (TRACES).
    Cheng Y; Wu L; Huang D; Wang Q; Fan Y; Zhang X; Fan H; Yao W; Liu B; Yu G; Pan Y; Xu F; He Z; Dong X; Ma R; Min X; Ge X; Chen H; Liu Q; Hu Y; Liu Y; Yang C; Yang Y; Li X; Zhou L
    Lung Cancer; 2024 Feb; 188():107455. PubMed ID: 38224653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Budget Impact of Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer.
    Schultz NM; O'Day K; Sugarman R; Ramaswamy K
    J Manag Care Spec Pharm; 2020 Apr; 26(4):538-549. PubMed ID: 32020841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The budget impact of introducing mobocertinib for the postplatinum treatment of advanced non-small cell lung cancer harboring epidermal growth factor receptor exon 20 insertion mutations.
    Hernandez L; Young M
    J Manag Care Spec Pharm; 2023 Feb; 29(2):172-186. PubMed ID: 36373869
    [No Abstract]   [Full Text] [Related]  

  • 15. New Advances in Supportive Care: Chemoprotective Agents as Novel Opportunities in Geriatric Oncology.
    Balducci L; Falandry C; List A
    Curr Oncol Rep; 2022 Dec; 24(12):1695-1703. PubMed ID: 35986858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-World Outcomes of Trilaciclib Among Patients with Extensive-Stage Small Cell Lung Cancer Receiving Chemotherapy.
    Goldschmidt J; Hart L; Scott J; Boykin K; Bailey R; Heritage T; Lopez-Gonzalez L; Zhou ZY; Edwards ML; Monnette A; Ogbonnaya A; Deyoung K; Venkatasetty D; Shi P; Aton L; Huang H; Conkling PR; Gordan L
    Adv Ther; 2023 Oct; 40(10):4189-4215. PubMed ID: 37490258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Budget Impact of Adding Ivabradine to Standard of Care in Patients with Chronic Systolic Heart Failure in the United States.
    Borer JS; Kansal AR; Dorman ED; Krotneva S; Zheng Y; Patel HK; Tavazzi L; Komajda M; Ford I; Böhm M; Kielhorn A
    J Manag Care Spec Pharm; 2016 Sep; 22(9):1064-71. PubMed ID: 27579829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myeloprotective Effects of Trilaciclib Among Patients with Small Cell Lung Cancer at Increased Risk of Chemotherapy-Induced Myelosuppression: Pooled Results from Three Phase 2, Randomized, Double-Blind, Placebo-Controlled Studies.
    Hussein M; Maglakelidze M; Richards DA; Sabatini M; Gersten TA; Lerro K; Sinielnikov I; Spira A; Pritchett Y; Antal JM; Malik R; Beck JT
    Cancer Manag Res; 2021; 13():6207-6218. PubMed ID: 34408488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial.
    Weiss JM; Csoszi T; Maglakelidze M; Hoyer RJ; Beck JT; Domine Gomez M; Lowczak A; Aljumaily R; Rocha Lima CM; Boccia RV; Hanna W; Nikolinakos P; Chiu VK; Owonikoko TK; Schuster SR; Hussein MA; Richards DA; Sawrycki P; Bulat I; Hamm JT; Hart LL; Adler S; Antal JM; Lai AY; Sorrentino JA; Yang Z; Malik RK; Morris SR; Roberts PJ; Dragnev KH;
    Ann Oncol; 2019 Oct; 30(10):1613-1621. PubMed ID: 31504118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Budget impact of tepotinib in the treatment of adult patients with metastatic non-small cell lung cancer harboring
    Stargardter M; McBride A; Tosh J; Sachdev R; Yang M; Ambavane A; Mittal M; Vioix H; Liu FX
    J Med Econ; 2021; 24(1):816-827. PubMed ID: 34126842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.